Gastrointestinal Cancer
Latest News
Advertisement
Latest Videos
CME Content
Advertisement
More News
Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.
Second-Line Treatment Approaches for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.
The COSMIC-312 Study in Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.
Fixed-dose eniluracil is being evaluated with escalating doses of capecitabine in patients with advanced, refractory gastrointestinal cancers, or in advanced GI cancers who are intolerant to fluoropyrimidine chemotherapy, as part of an open-label, phase 1b dose-escalation trial.
The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.
Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.
Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.
Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate in Western patients with HER2-positive gastric/gastroesophageal junction cancer.
Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.
The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.
Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.
HCC: IO in Liver Transplant Recipients
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.
The LEGACY Study in HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.
Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.
Pembrolizumab as an adjuvant therapy compared with placebo continued to showcase an impressive disease-free survival benefit in patients with clear cell renal cell carcinoma following nephrectomy, with improvement observed across subgroups.
The dismutase mimetic avasopasem manganese was found to improve overall survival, progression-free survival, local disease control, time to metastases, and tumor response rate compared with placebo in patients with unresectable or borderline resectable locally advanced pancreatic cancer who were undergoing stereotactic body radiation.
The FDA has accepted for review a biologics license application for tislelizumab as a potential therapeutic option in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma following previous systemic therapy.
Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.
Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr
Selecting First-Line Therapy for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
Frontline IO for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or gastroesophageal junction cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5